1. Home
  2. CHW vs ZVRA Comparison

CHW vs ZVRA Comparison

Compare CHW & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Global Dynamic Income Fund

CHW

Calamos Global Dynamic Income Fund

HOLD

Current Price

$8.55

Market Cap

563.9M

Sector

Finance

ML Signal

HOLD

Logo Zevra Therapeutics Inc.

ZVRA

Zevra Therapeutics Inc.

HOLD

Current Price

$12.32

Market Cap

562.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHW
ZVRA
Founded
N/A
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
563.9M
562.2M
IPO Year
2007
2015

Fundamental Metrics

Financial Performance
Metric
CHW
ZVRA
Price
$8.55
$12.32
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$23.00
AVG Volume (30 Days)
133.6K
867.0K
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
159.21
EPS
N/A
0.74
Revenue
N/A
$106,470,000.00
Revenue This Year
N/A
$37.27
Revenue Next Year
N/A
$53.42
P/E Ratio
N/A
$16.82
Revenue Growth
N/A
350.91
52 Week Low
$6.98
$7.16
52 Week High
$9.18
$15.04

Technical Indicators

Market Signals
Indicator
CHW
ZVRA
Relative Strength Index (RSI) 50.45 60.29
Support Level $8.38 $12.18
Resistance Level $8.81 $14.27
Average True Range (ATR) 0.11 0.37
MACD 0.00 0.10
Stochastic Oscillator 49.57 93.38

Price Performance

Historical Comparison
CHW
ZVRA

About CHW Calamos Global Dynamic Income Fund

Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities, and alternative investments.

About ZVRA Zevra Therapeutics Inc.

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Share on Social Networks: